Related Experiment Video
Updated: Mar 18, 2026
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
Abstract:
Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.
Insights
Cancer patients face significant risks from infections. These guidelines offer updated strategies for preventing and treating fungal and viral infections, including new treatments and monitoring.
Area of Science:
- Oncology
- Infectious Diseases
- Pharmacology
Background:
- Infectious diseases significantly contribute to cancer patient morbidity and mortality.
- The National Comprehensive Cancer Network (NCCN) provides guidelines for managing cancer-related infections.
- This update focuses on antifungal and antiviral prophylaxis strategies.
Purpose of the Study:
- To update recommendations for antifungal and antiviral prophylaxis in cancer patients.
- To incorporate new agents and therapeutic drug monitoring for fungal infections.
- To refine antiviral prophylaxis for hepatitis B and management of hepatitis C and HIV.
Main Methods:
- Review and synthesis of current evidence and expert consensus.
- Analysis of recent advancements in antifungal and antiviral therapies.
- Integration of updated guidelines for opportunistic infections.
Main Results:
- Expanded recommendations for antifungal prophylaxis, including new agents and therapeutic drug monitoring.
- Enhanced antiviral prophylaxis strategies for hepatitis B.
- Updated management considerations for hepatitis C and human immunodeficiency virus (HIV).
Conclusions:
- Updated NCCN Guidelines provide critical, evidence-based strategies for infection prevention in cancer patients.
- Prophylaxis recommendations for fungal and viral infections have evolved with new therapeutic options.
- These guidelines aim to reduce infection-related complications and improve outcomes for individuals undergoing cancer treatment.
